CI-1033PD 183805Canertinib |
Small molecule TKI |
Irreversible binding to ATP-binding site EGFR 1, 2, 3, 4 |
Phase II |
50 mg–200 mg daily day 1–21 (oral) |
Pfizer |
|
EKB-569Pelitinib |
Small molecule TKI |
Irreversible binding to TK domain of EGFR 1, 2, 4 |
None, Phase I in solid tumors |
25 mg daily (oral) |
Wyeth-Ayerst |
|
PKI-166 |
Small molecule TKI |
Reversible binding to TKI domain EGFR 1, 2 |
None, Phase I in solid tumors |
600 mg–700 mg 2 weeks on/off |
Novartis |
|
AV-412 |
Second generation dual TKI |
Reversible binding to TKI domain EGFR 1,2 |
None, active Phase I trial in solid tumors |
Dose escalation daily, dose escalation three times/wk |
AVEO Pharmaceuticals |
|
BIBW-2992Tovok |
Second generation dual TKI |
Irreversible binding to TKI domain EGFR 1, 2 |
None, Phase I in solid tumors and Phase II in lung, breast, cancer |
50 mg daily (oral), 70 mg daily 2weeks on/off |
Boehringer Ingelheim's |
|
CUDC-101 |
Small molecule TKI |
Multi-targeted HDAC/EGFR 1, 2 |
None, Phase I solid tumors |
Dose escalation, unknown starting dose |
Curis, Inc. |
|
BMS-690154 |
Small molecule TKI |
Binds tyrosine kinase domains of EFGR1, 2 and VEGFR-2 |
None, Phase I in combo with paclitaxel and carboplatin |
Dose escalation, unknown starting dose |
Bristol-Myers Squibb |
|
Matuzumab, EMD 72000 |
Humanized MAb |
Extracellular domain binding and ligand blockade |
Phase II EGFR+, other head+neck, lung, gastric |
800 mg weekly (IV) |
EMD Serono/Merk KGaA |
|
Pertuzumab |
Humanized MAb |
Extracellular her2 ligand blockade, prevents dimers with EGFR-1 |
Phase II, lung, breast, prostate |
840 mg load followed by 420 mg every 3 weeks (IV) |
Merck Serono |
|
RO5083945 |
Glycoengineered MAb |
Binds to EGFR extracellular domain, inhibits dimers |
None, Phase I EGFR+ solid tumors |
Dose escalation start at 50 mg (IV) |
Roche Pharmaceuticals |